500 руб
Журнал «Технологии живых систем» №2 за 2026 г.
Статья в номере:
Подопланин как современный опухолевый маркер: обзор литературы
Тип статьи: обзорная статья
DOI: https://doi.org/10.18127/j20700997-202602-01
УДК: 616-006-074:577.112:578.52(048.8)
Ключевые слова: Подопланин опухолевый маркер онкологические заболевания диагностика прогноз
Авторы:

И.А. Крупаткин1, А.В. Колпащиков2, А.В. Заборовский3, Н.Е. Кушлинский4

1–4 ФГБОУ ВО «Российский университет медицины» Минздрава России (Москва, Россия)

4 ФГБУ «Национальный медицинский исследовательский центр (НМИЦ) онкологии им. Н.Н. Блохина» Минздрава России (Москва, Россия)

1 krupatkin.sci@gmail.com, 2 kolpaschikov@mail.ru, 3 azabor@mail.ru, 4 kne3108@gmail.com

Аннотация:

Постановка проблемы. Подопланин – трансмембранный белок, регулирующий нормальные физиологические процессы, такие как формирование лимфатических сосудов, коагуляцию и иммунный ответ. Согласно современным представлениям, исследователи предполагают связь подопланина с канцерогенезом. Однако его роль в диагностике и оценке прогноза ряда онкологических заболеваний неоднозначна и это привлекает интерес многих исследователей к дискуссии по данной проблеме.

Цель работы – анализ значимости подопланина в диагностике и оценке прогноза онкологических заболеваний.

Результаты. Повышенная экспрессия подопланина выявлена в различных злокачественных опухолях и в большинстве из них ассоциируется с усилением злокачественности. Однако при онкологических заболеваниях его роль становится негативной: повышенная экспрессия подопланина способствует агрессивному росту опухоли, инвазии и метастазированию. Белок стимулирует подвижность раковых клеток, участвует в образовании метастазов через активацию тромбоцитов и поддерживает работу особых клеточных популяций, формирующих опухолевую микросреду. Благодаря этому подопланин является важным диагностическим и прогностическим маркером – согласно актуальным исследованиям, уровень его растворимой формы в крови связан со степенью злокачественности, метастазированием, риском ассоциированных коагулопатий и прогнозом выживаемости.

Практическая значимость. Подопланин является важным биологическим регулятором, перспективной мишенью для диагностики и лечения онкологических заболеваний, что делает его объектом изучения как в современной онкологии, в частности, так и в медицинской науке в целом.

Страницы: 5-25
Для цитирования

Крупаткин И.А., Колпащиков А.В., Заборовский А.В., Кушлинский Н.Е. Подопланин как современный опухолевый маркер: обзор литературы // Технологии живых систем. 2026. T. 23. № 2. С. 5-25. DOI: https://doi.org/10.18127/j20700997-202602-01

Список источников
  1. Quintanilla M., Montero-Montero L., Renart J., Martín-Villar E. Podoplanin in Inflammation and Cancer // Int J Mol Sci. 2019. Feb 6. V. 20(3). P. 707. DOI: 10.3390/ijms20030707
  2. Renart J., San Mauro D., Agorreta A. et al. Evolutionary history of the podoplanin gene // Gene Rep. 2018. V. 13. P. 28–37. DOI: 10.1016/j.genrep.2018.08.005
  3. Toyoshima M., Nakajima M., Yamori T., Tsuruo T. Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26 // Cancer Res. 1995 Feb 15. V. 55(4). P. 767–773.
  4. Kato Y., Fujita N., Kunita A. et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors // J. Biol. Chem. 2003 Dec 19. V. 278(51). P. 51599-51605. DOI: 10.1074/jbc.M309935200
  5. Takemoto A., Miyata K., Fujita N. Platelet-activating factor podoplanin: from discovery to drug development // Cancer Metastasis Rev. 2017 Jun. V. 36(2). P. 225-234. DOI: 10.1007/s10555-017-9672-2
  6. Cheok Y.Y., Tan G.M.Y., Chan Y.T. et al. Podoplanin and its multifaceted roles in mammalian developmental program // Cells Dev. 2024 Dec. V. 180. P. 203943. DOI: 10.1016/j.cdev.2024.203943
  7. Ozaki Y., Tamura S., Suzuki-Inoue K. New horizon in platelet function: with special reference to a recently-found molecule, CLEC-2 // Thromb. J. 2016 Oct 4. V. 14(Suppl 1). P. 27. DOI: 10.1186/s12959-016-0099-8
  8. Tal O., Lim H.Y., Gurevich I. et al. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling // J. Exp. Med. 2011 Sep 26. V. 208(10). P. 2141-2153. DOI: 10.1084/jem.20102392
  9. Fuertbauer E., Zaujec J., Uhrin P. et al. Thymic medullar conduits-associated podoplanin promotes natural regulatory T cells // Immunol. Lett. 2013 Jul-Aug. V. 154(1-2). P. 31-41. DOI: 10.1016/j.imlet.2013.07.007
  10. Cueni L.N., Detmar M. Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions // Exp. Cell Res. 2009 Jun 10. V. 315(10). P. 1715-1723. DOI: 10.1016/j.yexcr.2009.02.021
  11. Tsuneki M., Maruyama S., Yamazaki M. et al. Extracellular heat shock protein A9 is a novel interaction partner of podoplanin in oral squamous cell carcinoma cells // Biochem. Biophys. Res. Commun. 2013 Apr 26. V. 434(1). P. 124-130. DOI: 10.1016/j.bbrc.2013.03.057
  12. Nakazawa Y., Sato S., Naito M. et al. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis // Blood. 2008 Sep 1. V. 112(5). P. 1730-1739. DOI: 10.1182/blood-2007-11-124693
  13. Martín-Villar E., Fernández-Muñoz B., Parsons M. et al. Podoplanin associates with CD44 to promote directional cell migration // Mol. Biol. Cell. 2010 Dec. V. 21(24). P. 4387-4399. DOI: 10.1091/mbc.E10-06-0489
  14. Martín-Villar E., Megías D., Castel S. et al. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition // J. Cell Sci. 2006 Nov 1. V. 119(Pt 21). P. 4541-4553. DOI: 10.1242/jcs.03218
  15. Li Y.Y., Zhou C.X., Gao Y. Podoplanin promotes the invasion of oral squamous cell carcinoma in coordination with MT1-MMP and Rho GTPases // Am. J. Cancer Res. 2015 Jan 15. V. 5(2). P. 514-529. Erratum in: Am. J. Cancer Res. 2022 Mar 15. V. 12(3). P. 1433-1434.
  16. Martín-Villar E., Scholl F.G., Gamallo C. et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas // Int. J. Cancer. 2005 Mar 1. V. 113(6). P. 899-910. DOI: 10.1002/ijc.20656
  17. Sekiguchi T., Takemoto A., Takagi S. et al. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis // Oncotarget. 2016 Jan 26. V. 7(4). P. 3934-3946. DOI: 10.18632/oncotarget.6598
  18. Troncoso M.F., Ferragut F., Bacigalupo M.L. et al. Galectin-8: a matricellular lectin with key roles in angiogenesis // Glycobiology. 2014 Oct. V. 24(10). P. 907-914. DOI: 10.1093/glycob/cwu054
  19. Kerjaschki D., Regele H.M., Moosberger I. et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates // J. Am. Soc. Nephrol. 2004 Mar. V. 15(3). P. 603-612. DOI: 10.1097/01.asn.0000113316.52371.2e
  20. Tsuneki M., Maruyama S., Yamazaki M. et al. Extracellular heat shock protein A9 is a novel interaction partner of podoplanin in oral squamous cell carcinoma cells // Biochem. Biophys. Res. Commun. 2013 Apr 26. V. 434(1). P. 124-130. DOI: 10.1016/j.bbrc.2013.03.057
  21. Sheng M., Sun R., Fu J., Lu G. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis. BMC Cancer. 2024 Apr 1;24(1):399. DOI: 10.1186/s12885-024-12194-w. PMID: 38561690; PMCID: PMC10983743.
  22. Suzuki-Inoue K., Inoue O., Ding G. et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets //
    J. Biol. Chem. 2010 Aug 6. V. 285(32). P. 24494-24507. DOI: 10.1074/jbc.M110.130575
  23. Uhrin P., Zaujec J., Breuss J.M. et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation // Blood. 2010 May 13. V. 115(19). P. 3997–4005. DOI: 10.1182/blood-2009-04-216069
  24. Hess P.R., Rawnsley D.R., Jakus Z. et al. Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life // J. Clin. Invest. 2014. V. 124(01). P. 273–284.
  25. Lowe K.L., Finney B.A., Deppermann C. et al. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development // Blood. 2015. V. 125(24). P. 3769–3777.
  26. Boulaftali Y., Hess P.R., Getz T.M. et al. Platelet ITAM signaling is critical for vascular integrity in inflammation // J. Clin. Invest. 2013. V. 123(02). P. 908–916.
  27. Gros A., Syvannarath V., Lamrani L. et al. Single platelets seal neutrophil-induced vascular breaches via GPVI during immunecomplex-mediated inflammation in mice // Blood. 2015. V. 126(08). P. 1017–1026.
  28. Asai J., Hirakawa S., Sakabe J. et al. Platelets regulate the migration of keratinocytes via podoplanin/CLEC-2 signaling during cutaneous wound healing in mice // Am. J. Pathol. 2016. V. 186(01). P. 101–108.
  29. Meyer J., Lejmi E., Fontana P. et al. A focus on the role of platelets in liver regeneration: do plateletendothelial cell interactions initiate the regenerative process? // J. Hepatol. 2015. V. 63(05). P. 1263–1271.
  30. Kono H., Fujii H., Suzuki-Inoue K. et al. The platelet-activating receptor C-type lectin receptor-2 plays an essential role in liver regeneration after partial hepatectomy in mice // J. Thromb. Haemost. 2017. V. 15(05). P. 998–1008.
  31. Van Raemdonck K., Umar S., Shahrara S. The pathogenic importance of CCL21 and CCR7 in rheumatoid arthritis // Cytokine Growth Factor Rev. 2020 Oct. V. 55. P. 86–93. DOI: 10.1016/j.cytogfr.2020.05.007
  32. Han L., Zhang L. CCL21/CCR7 axis as a therapeutic target for autoimmune diseases // Int. Immunopharmacol. 2023 Aug. V. 121. P. 110431. DOI: 10.1016/j.intimp.2023.110431
  33. Chen W.S., Cao Z., Sugaya S. et al. Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3 // Nat. Commun. 2016 Apr 12. V. 7. P. 11302. DOI: 10.1038/ncomms11302
  34. Shi J., Chen Y., Zhao W. et al. Galectin-8 involves in arthritic condylar bone loss via podoplanin/AKT/ERK axis-mediated inflammatory lymphangiogenesis // Osteoarthritis Cartilage. 2023 Jun. V. 31(6). P. 753–765. DOI: 10.1016/j.joca.2023.01.008
  35. Bieniasz-Krzywiec P., Mazzone M. PoEMs edit breast cancer outcome // Aging (Albany NY). 2020 Feb 26. V. 12(5). P. 4045–4047. DOI: 10.18632/aging.102870
  36. Erovic B.M., Neuchrist C., Kandutsch S. et al. CD9 expression on lymphatic vessels in head and neck mucosa // Mod. Pathol. 2003 Oct. V. 16(10). P. 1028-1034. DOI: 10.1097/01.MP.0000089777.58000.B2
  37. Yáñez-Mó M., Barreiro O., Gordon-Alonso M. et al. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes // Trends Cell Biol. 2009 Sep. V. 19(9). P. 434-446. DOI: 10.1016/j.tcb.2009.06.004
  38. de Winde C.M., Makris S., Millward L.J. et al. Fibroblastic reticular cell response to dendritic cells requires coordinated activity of podoplanin, CD44 and CD9 // J. Cell Sci. 2021 Jul 15. V. 134(14). P. jcs258610. DOI: 10.1242/jcs.258610
  39. Sikorska J., Gaweł D., Domek H. et al. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases // BMC Cancer. 2019 Jan 17. V. 19(1). P. 85. DOI: 10.1186/s12885-018-5239-z
  40. Tanaka K., Tanaka M., Watanabe N. et al. C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes // Sci. Rep. 2022 Dec 26. V. 12(1). P. 22356. DOI: 10.1038/s41598-022-26456-9
  41. Khalili-Tanha G., Radisky E.S., Radisky D.C., Shoari A. Matrix metalloproteinase-driven epithelial-mesenchymal transition: implications in health and disease // J. Transl. Med. 2025 Apr 11. V. 23(1). P. 436. DOI: 10.1186/s12967-025-06447-w
  42. Mishima K., Kato Y., Kaneko M.K. et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression // Acta Neuropathol. 2006 May. V. 111(5). P. 483–488. DOI: 10.1007/s00401-006-0063-y
  43. Mishima K., Kato Y., Kaneko M.K. et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma // Acta Neuropathol. 2006 Jun. V. 111(6). P. 563–568. DOI: 10.1007/s00401-006-0033-4
  44. Abe S., Morita Y., Kaneko M.K. et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody //
    J. Immunol. 2013 Jun 15. V. 190(12). P. 6239–6249. DOI: 10.4049/jimmunol.1300448
  45. Chang M.C., Vargas S.O., Hornick J.L. et al. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors // Int. J. Gynecol. Pathol. 2009 Jul. V. 28(4). P. 347-355. DOI: 10.1097/PGP.0b013e318195da86
  46. Takagi S., Oh-hara T., Sato S. et al. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis // Int. J. Cancer. 2014 Jun 1. V. 134(11). P. 2605–2614. DOI: 10.1002/ijc.28602
  47. Kato Y., Sasagawa I., Kaneko M. et al. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors // Oncogene. 2004 Nov 4. V. 23(52). P. 8552–8556. DOI: 10.1038/sj.onc.1207869
  48. Ariizumi T., Ogose A., Kawashima H. et al. Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors // Pathol. Int. 2010 Mar. V. 60(3). P. 193–202. DOI: 10.1111/j.1440-1827.2009.02510.x
  49. Suzuki H., Kaneko M.K., Kato Y. Roles of Podoplanin in Malignant Progression of Tumor // Cells. 2022 Feb 7. V. 11(3). P. 575. DOI: 10.3390/cells11030575
  50. Wang X., Wang X., Carvalho V. et al. Prognostic Value of Podoplanin in Various Tumors // Technol. Cancer Res. Treat. 2021 Jan-Dec. V. 20. P. 15330338211038142. DOI: 10.1177/15330338211038142
  51. Sankiewicz A., Guszcz T., Mena-Hortelano R. et al. Podoplanin serum and urine concentration in transitional bladder cancer // Cancer Biomark. 2016. V. 16(3). P. 343-350. DOI: 10.3233/CBM-160572
  52. Zhao X., Pan Y., Ren W. et al. Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis // Cancer Sci. 2018 Feb. V. 109(2). P. 403–411. DOI: 10.1111/cas.13475
  53. Mello F.W., Kammer P.V., Silva C.A.B. et al. Prognostic and clinicopathological significance of podoplanin immunoexpression in oral and oropharyngeal squamous cell carcinoma: A systematic review // J. Oral Pathol. Med. 2021 Jan. V. 50(1). P. 1–9. DOI: 10.1111/jop.13041
  54. Petrova T.V., Mäkinen T., Mäkelä T.P. et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor // EMBO J. 2002 Sep 2. V. 21(17). P. 4593–4599. DOI: 10.1093/emboj/cdf470
  55. Hantusch B., Kalt R., Krieger S. et al. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells // BMC Mol. Biol. 2007 Mar 7. V. 8. P. 20. DOI: 10.1186/1471-2199-8-20
  56. Durchdewald M., Guinea-Viniegra J., Haag D. et al. Podoplanin is a novel fos target gene in skin carcinogenesis // Cancer Res. 2008 Sep 1. V. 68(17). P. 6877–6883. DOI: 10.1158/0008-5472.CAN-08-0299
  57. Kunita A., Kashima T.G., Ohazama A. et al. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma // Am. J. Pathol. 2011 Aug. V. 179(2). P. 1041-9. DOI: 10.1016/j.ajpath.2011.04.027
  58. Shen Y., Chen C.S., Ichikawa H., Goldberg G.S. SRC induces podoplanin expression to promote cell migration // J. Biol. Chem. 2010 Mar 26. V. 285(13). P. 9649–9656. DOI: 10.1074/jbc.M109.047696
  59. Peterziel H., Müller J., Danner A. et al. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation // Neuro Oncol. 2012 Apr. V. 14(4). P. 426–439. DOI: 10.1093/neuonc/nos055
  60. Mei Y., Zhang P., Zuo H. et al. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis // Oncogene. 2014 Jul 17.
    V. 33(29). P. 3839–3850. DOI: 10.1038/onc.2013.354
  61. Kunita A., Baeriswyl V., Meda C. et al. Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front // Am. J. Pathol. 2018 May. V. 188(5). P. 1276–1288. DOI: 10.1016/j.ajpath.2018.01.016
  62. Kreso A., Dick J.E. Evolution of the cancer stem cell model // Cell Stem Cell. 2014 Mar 6. V. 14(3). P. 275–291. DOI: 10.1016/j.stem.2014.02.006
  63. Massagué J., Obenauf A.C. Metastatic colonization by circulating tumour cells // Nature. 2016 Jan 21. V. 529(7586). P. 298–306. DOI: 10.1038/nature17038
  64. Cojoc M., Mäbert K., Muders M.H., Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms // Semin. Cancer Biol. 2015 Apr. V. 31. P. 16–27. DOI: 10.1016/j.semcancer.2014.06.004
  65. Bortolomai I., Canevari S., Facetti I. et al. Tumor initiating cells: development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension // Cell Cycle. 2010 Mar 15. V. 9(6). P. 1194–1206. DOI: 10.4161/cc.9.6.11108
  66. Miyashita T., Higuchi Y., Kojima M. et al. Single cell time-lapse analysis reveals that podoplanin enhances cell survival and colony formation capacity of squamous cell carcinoma cells // Sci. Rep. 2017 Jan 6. V. 7. P. 39971. DOI: 10.1038/srep39971
  67. Shimada Y., Ishii G., Nagai K. et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung // Cancer Sci. 2009 Nov. V. 100(11). P. 2054–2059. DOI: 10.1111/j.1349-7006.2009.01295.x
  68. Nishijima N., Ishii G., Nagai K. et al. Cancer-initiating cell marker-positive cells generate metastatic tumors that recapitulate the histology of the primary tumors // Pathol. Int. 2013 Feb. V. 63(2). P. 94–101. DOI: 10.1111/pin.12039
  69. Islam F., Gopalan V., Wahab R. et al. Cancer stem cells in oesophageal squamous cell carcinoma: Identification, prognostic and treatment perspectives // Crit. Rev. Oncol. Hematol. 2015 Oct. V. 96(1). P. 9-19. DOI: 10.1016/j.critrevonc.2015.04.007
  70. Dahlrot R.H., Hermansen S.K., Hansen S., Kristensen B.W. What is the clinical value of cancer stem cell markers in gliomas? // Int. J. Clin. Exp. Pathol. 2013. V. 6(3). P. 334–348.
  71. Kalluri R., Zeisberg M. Fibroblasts in cancer // Nat. Rev. Cancer. 2006 May. V. 6(5). P. 392-401. DOI: 10.1038/nrc1877
  72. Calon A., Tauriello D.V., Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis // Semin. Cancer Biol. 2014 Apr. V. 25. P. 15–22. DOI: 10.1016/j.semcancer.2013.12.008
  73. Pula B., Witkiewicz W., Dziegiel P., Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review // Int. J. Oncol. 2013 Jun. V. 42(6). P. 1849–1857. DOI: 10.3892/ijo.2013.1887
  74. Shindo K., Aishima S., Ohuchida K. et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas // Mol. Cancer. 2013 Dec 20. V. 12(1). P. 168. DOI: 10.1186/1476-4598-12-168
  75. Obulkasim H., Shi X., Wang J. et al. Podoplanin is an important stromal prognostic marker in perihilar cholangiocarcinoma // Oncol. Lett. 2018 Jan. V. 15(1). P. 137–146. DOI: 10.3892/ol.2017.7335
  76. Cui M., Dong H., Duan W. et al. The relationship between cancer associated fibroblasts biomarkers and prognosis of breast cancer: a systematic review and meta-analysis // PeerJ. 2024 Feb 23. V. 12. P. e16958. DOI: 10.7717/peerj.16958
  77. Irvine A.F., Waise S., Green E.W. et al. Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis // Sci. Rep. 2021 Feb 12. V. 11(1). P. 3727. DOI: 10.1038/s41598-021-81796-2
  78. Luanpitpong S., Wang L., Castranova V. et al. Induction of cancer-associated fibroblast-like cells by carbon nanotubes dictates its tumorigenicity // Sci. Rep. 2016 Dec 20. V. 6. P. 39558. DOI: 10.1038/srep39558
  79. Yoshida T., Ishii G., Goto K. et al. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation // Clin. Cancer Res. 2015 Feb 1. V. 21(3). P. 642–651. DOI: 10.1158/1078-0432.CCR-14-0846
  80. Gao H., Wong S.Q.R., Subel E. et al. Caspase-1-dependent pyroptosis converts αSMA+ CAFs into collagen-IIIhigh iCAFs to fuel chemoresistant cancer stem cells // Sci. Adv. 2025 Jun 13. V. 11(24). P. eadt8697. DOI: 10.1126/sciadv.adt8697
  81. Dallavalasa S., Beeraka N.M., Basavaraju C.G. et al. The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis - Current Status // Curr. Med. Chem. 2021. V. 28(39). P. 8203–8236. DOI: 10.2174/0929867328666210720143721
  82. Lafta H.A., AbdulHussein A.H., Al-Shalah S.A.J. et al. Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products // Curr. Top. Med. Chem. 2023. V. 23(12). P. 1104–1122. DOI: 10.2174/1568026623666230201145909
  83. Bieniasz-Krzywiec P., Martín-Pérez R., Ehling M. et al. Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer // Cell Metab. 2019 Nov 5. V. 30(5). P. 917–936.e10. DOI: 10.1016/j.cmet.2019.07.015
  84. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. 2011 Mar 4. V. 144(5). P. 646–674. DOI: 10.1016/j.cell.2011.02.013
  85. Masi I., Caprara V., Bagnato A., Rosanò L. Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation // Front. Cell Dev. Biol. 2020 Oct 15. V. 8. Article 584181. DOI: 10.3389/fcell.2020.584181
  86. Martín-Villar E., Borda-d'Agua B., Carrasco-Ramirez P. et al. Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability // Oncogene. 2015 Aug 20. V. 34(34). P. 4531–4544. DOI: 10.1038/onc.2014.388
  87. Te Boekhorst V., Preziosi L., Friedl P. Plasticity of Cell Migration In Vivo and In Silico // Annu. Rev. Cell Dev. Biol. 2016 Oct 6. V. 32. P. 491-526. DOI: 10.1146/annurev-cellbio-111315-125201
  88. Stuelten C.H., Parent C.A., Montell D.J. Cell motility in cancer invasion and metastasis: insights from simple model organisms // Nat. Rev. Cancer. 2018 May. V. 18(5). P. 296–312. DOI: 10.1038/nrc.2018.15
  89. Wicki A., Lehembre F., Wick N. et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton // Cancer Cell. 2006 Apr. V. 9(4). P. 261–272. DOI: 10.1016/j.ccr.2006.03.010
  90. Tozluoğlu M., Tournier A.L., Jenkins R.P. et al. Matrix geometry determines optimal cancer cell migration strategy and modulates response to interventions // Nat. Cell Biol. 2013 Jul. V. 15(7). P. 751–762. DOI: 10.1038/ncb2775
  91. Wyckoff J.B., Pinner S.E., Gschmeissner S. et al. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo // Curr. Biol. 2006 Aug 8. V. 16(15). P. 1515-23. DOI: 10.1016/j.cub.2006.05.065
  92. de Winde C.M., George S.L., Crosas-Molist E. et al. Podoplanin drives dedifferentiation and amoeboid invasion of melanoma // iScience. 2021 Aug 13. V. 24(9). P. 102976. DOI: 10.1016/j.isci.2021.102976
  93. Braun A., Anders H.J., Gudermann T., Mammadova-Bach E. Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues // Front. Oncol. 2021 Jul 12. V. 11. P. 665534. DOI: 10.3389/fonc.2021.665534
  94. David C.J., Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer // Nat. Rev. Mol. Cell Biol. 2018 Jul. V. 19(7). P. 419–435. DOI: 10.1038/s41580-018-0007-0
  95. Suzuki J., Aokage K., Neri S. et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma // Lung Cancer. 2021 Mar. V. 153. P. 1–10. DOI: 10.1016/j.lungcan.2020.12.020
  96. Nakamura H., Ichikawa T., Nakasone S. et al. Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions // Lung Cancer. 2018 Jan. V. 115. P. 56–63. DOI: 10.1016/j.lungcan.2017.11.013
  97. Pula B., Jethon A., Piotrowska A. et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma // Histopathology. 2011 Dec. V. 59(6). P. 1249–1260. DOI: 10.1111/j.1365-2559.2011.04060.x
  98. Shindo K., Aishima S., Ohuchida K. et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas // Mol. Cancer. 2013 Dec 20. V. 12(1). P. 168. DOI: 10.1186/1476-4598-12-168
  99. Sakai T., Aokage K., Neri S. et al. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma // Lung Cancer. 2018 Dec. V. 126. P. 64–71. DOI: 10.1016/j.lungcan.2018.10.021
  100. Komohara Y., Jinushi M., Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors // Cancer Sci. 2014 Jan. V. 105(1). P. 1–8. DOI: 10.1111/cas.12314
  101. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome // Nat. Rev. Cancer. 2012 Mar 15. V. 12(4). P. 298–306. DOI: 10.1038/nrc3245
  102. Peters A., Burkett P.R., Sobel R.A. et al. Podoplanin negatively regulates CD4+ effector T cell responses // J. Clin. Invest. 2015 Jan. V. 125(1). P. 129–140. DOI: 10.1172/JCI74685
  103. Chihara N., Madi A., Kondo T. et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells // Nature. 2018 Jun. V. 558(7710). P. 454–459. DOI: 10.1038/s41586-018-0206-z
  104. Qin S., Xu L., Yi M. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 // Mol. Cancer. 2019 Nov 6. V. 18(1). P. 155. DOI: 10.1186/s12943-019-1091-2
  105. Tatsumi K. The pathogenesis of cancer-associated thrombosis // Int. J. Hematol. 2024 May. V. 119(5). P. 495–504. DOI: 10.1007/s12185-024-03735-x
  106. Gi T., Kuwahara A., Yamashita A. et al. Histopathological Features of Cancer-Associated Venous Thromboembolism: Presence of Intrathrombus Cancer Cells and Prothrombotic Factors // Arterioscler. Thromb. Vasc. Biol. 2023 Jan. V. 43(1). P. 146–159. DOI: 10.1161/ATVBAHA.122.318463
  107. Diaz M., Jo J. Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients // Curr. Oncol. Rep. 2022 Apr. V. 24(4). P. 493–500. DOI: 10.1007/s11912-021-01178-9
  108. Riedl J., Preusser M., Nazari P.M. et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism // Blood. 2017 Mar 30. V. 129(13). P. 1831–1839. DOI: 10.1182/blood-2016-06-720714
  109. Kapteijn M.Y., Bakker N., Koekkoek J.A.F. et al. Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications // Thromb. Haemost. 2025 May. V. 125(5). P. 421-434. DOI: 10.1055/s-0044-1789592
  110. Thaler J., Ay C., Kaider A. et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas // Neuro Oncol. 2014 Dec. V. 16(12). P. 1645–1651. DOI: 10.1093/neuonc/nou106
  111. Jo J., Diaz M., Horbinski C. et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review // Neuro Oncol. 2023 Aug 3. V. 25(8). P. 1381–1394. DOI: 10.1093/neuonc/noad059
  112. Prouse T., Mohammad M.A., Ghosh S. et al. Pancreatic Cancer and Venous Thromboembolism // Int. J. Mol. Sci. 2024 May 23.
    V. 25(11). P. 5661. DOI: 10.3390/ijms25115661
  113. Hirayama K., Kono H., Nakata Y. et al. Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer // Surg. Today. 2018 Jan. V. 48(1). P. 110–118. DOI: 10.1007/s00595-017-1559-x
  114. Pelegrín-Mateo F.J., Zambrano C.B., Vázquez E.B. et al. Cancer genetic profile and risk of thrombosis // Eur. J. Intern. Med. 2025 Jun. V. 136. P. 19-26. DOI: 10.1016/j.ejim.2025.04.004
  115. Wang X., Liu B., Xu M. et al. Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis // Thromb. Res. 2021 Apr. V. 200. P. 72–80. DOI: 10.1016/j.thromres.2021.01.008
  116. Tawil N., Bassawon R., Meehan B. et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles // Blood Adv. 2021. V. 5. P. 1682–1694. DOI: 10.1182/bloodadvances.2020002998
  117. Meng D., Luo M., Liu B. The Role of CLEC-2 and Its Ligands in Thromboinflammation // Front. Immunol. 2021 Jun 9. V. 12. Article 688643. DOI: 10.3389/fimmu.2021.688643
  118. Shirai T., Tsukiji N., Sasaki T. et al. Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model // J. Thromb. Haemost. 2023 Nov. V. 21(11). P. 3153-3165. DOI: 10.1016/j.jtha.2023.07.005
  119. Sasano T., Gonzalez-Delgado R., Muñoz N.M. et al. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer // J. Thromb. Haemost. 2022 Jan. V. 20(1). P. 104-114. DOI: 10.1111/jth.15544
  120. Pan Y. et al. Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets // Blood, The Journal of the American Society of Hematology. 2014. V. 124. P. 3656–3665.
  121. Carrasco-Ramírez P. et al. Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation // Oncotarget. 2016. V. 7. P. 16070.
  122. Mege D. et al. The origin and concentration of circulating microparticles differ according to cancer type and evolution: A prospective single‐center study // International journal of cancer. 2016. V. 138. P. 939–948.
  123. Kemi N., Eskuri M., Herva A. et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma // Br. J. Cancer. 2018 Aug.
    V. 119(4). P. 435-439. DOI: 10.1038/s41416-018-0202-y
  124. Takiguchi K., Shoda K., Nakayama T. et al. Soluble podoplanin as a biomarker in diffuse type gastric cancer // Oncol. Rep. 2022 Mar. V. 47(3). P. 51. DOI: 10.3892/or.2022.8262
  125. Zhu X., Xu M., Zhao X. et al. The Detection of Plasma Soluble Podoplanin of Patients with Breast Cancer and Its Clinical Signification // Cancer Manag Res. 2020 Dec 23. V. 12. P. 13207-13214. DOI: 10.2147/CMAR.S281785
  126. Zhang Q., Peng K., Wang L. et al. Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer // Clin. Appl. Thromb. Hemost. 2023 Jan-Dec. V. 29. Article. 10760296231183432. DOI: 10.1177/10760296231183432
  127. Meliante P.G., Pizzolante S., Perna L. et al. Molecular Markers of Occult Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients // Front. Biosci. (Landmark Ed). 2025 Feb 20. V. 30(2). P. 25267. DOI: 10.31083/FBL25267
  128. Kato Y., Kaneko M.K., Kuno A. et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain // Biochem. Biophys. Res. Commun. 2006 Nov 3. V. 349(4). P. 1301–1307. DOI: 10.1016/j.bbrc.2006.08.171
  129. Nakazawa Y., Takagi S., Sato S. et al. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies // Cancer Sci. 2011 Nov. V. 102(11). P. 2051–2057. DOI: 10.1111/j.1349-7006.2011.02058.x
  130. Takagi S., Sato S., Oh-hara T. et al. Platelets promote tumor growth and metastasis via direct interaction between
    Aggrus/podoplanin and CLEC-2 // PLoS One. 2013 Aug 21. V. 8(8). P. e73609. DOI: 10.1371/journal.pone.0073609
  131. Tsao L.C., Force J., Hartman Z.C. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies // Cancer Res. 2021 Sep 15. V. 81(18). P. 4641-4651. DOI: 10.1158/0008-5472.CAN-21-1109
  132. Kato Y., Kaneko M.K. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin // Sci. Rep. 2014 Aug 1. V. 4. P. 5924. DOI: 10.1038/srep05924
  133. Ukaji T., Takemoto A., Katayama R. et al. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis) // Oncotarget. 2018 Sep 7. V. 9(70). P. 33322-33336. DOI: 10.18632/oncotarget.26055
  134. Ward P.L., Koeppen H., Hurteau T., Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells // J. Exp. Med. 1989 Jul 1. V. 170(1). P. 217-32. DOI: 10.1084/jem.170.1.217
  135. Suzuki H., Ohishi T., Kaneko M.K., Kato Y. A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models // Cancers (Basel). 2023 Oct 20. V. 15(20).
    P. 5080. DOI: 10.3390/cancers15205080
  136. Tanaka T., Suzuki H., Ohishi T. et al. Antitumor Activities by a Humanized Cancer-Specific Anti-Podoplanin Monoclonal Antibody humPMab-117 Against Human Tumors // Cancer Sci. 2025 Aug. V. 116(8). P. 2232-2242. DOI: 10.1111/cas.70103
Дата поступления: 25.12.2025
Одобрена после рецензирования: 02.02.2026
Принята к публикации: 04.03.2026